MedCity News September 15, 2024
Frank Vinluan

Roche’s Tecentriq Hybreza is a subcutaneously injectable formulation of the cancer drug Tecentriq while Ocrevus Zunovo is an injectable version of multiple sclerosis drug Ocrevus. Each is administered in minutes compared to an hour or more for infused therapies.

Biologic drugs are typically given as infusions that can take an hour or longer. The FDA has approved injectable versions of two biologic Roche drugs, one for multiple sclerosis and the other for cancer. Each one shaves a patient’s dosing time down to minutes.

The cancer drug approval went to Tecentriq Hybreza, a subcutaneously injectable version of the Roche immunotherapy Tecentriq. Dosing is a seven-minute injection in the thigh every three weeks. By comparison, IV infusion of Tecentriq takes about 30...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Related Articles:
Pharma Pulse: 9/18/24: How Drug Shortages Affect Pharmacovigilance, Long Strange Trip Continues for Psychedelics & more
Navigating the AI 'hype cycle': Bayer, Daiichi Sankyo and argenx leaders on implementing AI into biopharma marketing
PBM strikes back at FTC over drug pricing report
Lilly expands Ireland manufacturing with $1.8 billion investment
Harris’ AG past hints at tough pharma stance

Share This Article